DGAP-News: STADA Arzneimittel AG: Legal action against

DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous STADA Arzneimittel AG: Legal action against STADA's Serbian subsidiary has been resolved 18.12.2015 / 14:05 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Bad Vilbel, December 18, 2015 - The insolvency administrator of Velefarm Holding as well as Velefarm VFB and the Serbian Hemofarm A.D., a subsidiary of STADA Arzneimittel AG, have today, on December 18, 2015 agreed on the resolution of a legal dispute. The settlement relates to the legal action taken by the insolvency administrator against Hemofarm, among others, in Belgrade's commercial court in February 2014 (see ad hoc release from February 14, 2014). At that time, the insolvency administrator had demanded that certain agreements and statements from the years 2010 and 2011 that had been reached between Hemofarm and companies of the Serbian wholesale group Velefarm with regard to the insolvent assets of Velefarm Holding and Velefarm VFB be declared invalid and, as a result, repayments to the insolvent assets be made. Within the scope of the settlement, the insolvency administrator waives his original claim in the amount of Euro 54.2 million (in local currency) which he had filed in court. In return, Hemofarm waives most of a claim in the single-digit million euro range which was already fully impaired by STADA in 2010. "Resolution of the legal dispute, which we believed from the beginning was unfounded, confirms our previous confidence in the Serbian legal system", says Dr. Matthias Wiedenfels, Chief Business Development & Central Services Officer at STADA Arzneimittel AG. "In view of the high priority that our Serbian location has in the Group, it is important that the dispute has been resolved. This means that there continues to be a good basis for the successful cooperation with our Serbian colleagues", says Hartmut Retzlaff, Chairman of the Executive Board at STADA Arzneimittel AG. Additional information for analysts: STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad Vilbel - Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de Additional information for journalists: STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad Vilbel - Germany / Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: press@stada.de Or visit us in the Internet at www.stada.com. --------------------------------------------------------------------------- 18.12.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: STADA Arzneimittel AG Stadastraße 2-18 61118 Bad Vilbel Germany Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: communications@stada.de Internet: www.stada.de ISIN: DE0007251803, DE0007251845, WKN: 725180, 725184, Indices: MDAX Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 425077 18.12.2015